Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative antiviral therapies to address severe viral infections. Primarily focused on the treatment of COVID-19 and hepatitis C, Atea is at the forefront of therapeutics that target unmet medical needs with its proprietary Purine Nucleotide Prodrug Technology Platform. This platform is used to suppress viral replication by selectively targeting viral RNA polymerases. Atea Pharmaceuticals partners with industry leaders and medical research institutions to accelerate the development of its drug candidates. The company plays a critical role in the pharmaceutical sector by contributing to global efforts in managing pandemics and improving public health outcomes through advanced scientific approaches. With its headquarters in Boston, Massachusetts, Atea is positioned within the deeply connected hub of biotechnology innovation and continues to hold a significant place in the healthcare sector by driving forward the potential of antiviral treatments.